This is a the United States news story, published by BBC UK, that relates primarily to EMA news.
For more the United States news, you can click here:
more the United States newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from BBC UK, you can click here:
more news from BBC UKOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Alzheimerâs treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest European Medicines Agency news, Alzheimerâs patients news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Scottish Medicines ConsortiumBBC UK
•83% Informative
Lecanemab works by clearing a rogue protein called amyloid, which builds up in the brains of Alzheimerâs patients.
The drug was approved in the United States earlier this year .
The EMA said the benefits of the treatment did not outweigh the risks of bleeding and swelling in the brain.
VR Score
89
Informative language
92
Neutral language
55
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links